Evidence map›Paper›PMID 33947337›Full record

Trial reportBMC infectious diseases2021

Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.

Maria Giovanna Quaranta, Luigina Ferrigno, Xhimi Tata, Franca D'Angelo, Carmine Coppola, Alessia Ciancio, Serena Rita Bruno, Martina Loi, Alessia Giorgini, Marzia Margotti and 12 more

Open access · goldAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. From Cure to Complexity: Post-SVR Liver and Metabolic Trajectories in Diabetic Patients.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Screening strategy to advance HCV elimination in Italy: a cost-consequence analysis.The European journal of health economics : HEPAC : health economics in prevention and care · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 17 institutions in 2 countries.

Maria Giovanna QuarantaCenter for Global Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.
Luigina FerrignoCenter for Global Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.
Xhimi TataUniversity of Tor Vergata, Nostra Signora del Buon Consiglio di Tirana, Tirana, Albania.
Franca D'AngeloCenter for Global Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.
Carmine CoppolaDepartment of Hepatology, Gragnano Hospital, Naples, Italy.
Alessia CiancioGastroenterology Unit, University of Turin, Turin, Italy.
Serena Rita BrunoInfectious Diseases, Ospedali Riuniti, Foggia, Italy.
Martina LoiLiver Unit, University Hospital, Monserrato, Cagliari, Italy.
Alessia GiorginiDepartment of Health Sciences, San Paolo Hospital, University of Milan, Milan, Italy.
Marzia MargottiDepartment of Internal Medicine, University Hospital of Modena, Modena, Italy.
Valentina CossigaDepartment of Clinical Medicine and Surgery, Federico II University, Naples, Italy.
Giuseppina BrancaccioDepartment of Infectious Disease, University of Padua, Padua, Italy.
Marcello DallioDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
Martina De SienaDepartment of Internal Medicine and Gastroenterology, Fondazione Policlinico A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Marco CannizzaroInternal Medicine, Villa Sofia-Cervello Hospital, Palermo, Italy.
Luisa CavallettoDepartment of Medicine, University Hospital of Padua, Padua, Italy.
Marco MassariInfectious Diseases, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Maria MazzitelliDepartment of Infectious Disease, University Hospital Mater Domini, Catanzaro, Italy.
Pasqualina De LeoDepartment of Infectious Disease, San Paolo Hospital, Savona, Italy.
Diletta LaccabueUnit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
Leonardo BaiocchiDepartment of Medical Sciences, University of Tor Vergata, Rome, Italy.
Loreta A KondiliCenter for Global Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy. loreta.kondili@iss.it.
Istituto Superiore di Sanità · ITUniversity of Padua · ITAzienda Ospedaliero Universitario Mater Domini · ITAzienda Sanitaria Unità Locale di Reggio Emilia · ITBedër University · ALFederico II University Hospital · ITOspedale di Parma · ITOspedale San Paolo · ITOspedale Vincenzo Cervello · ITOspedali Riuniti di Foggia · ITUniversità Cattolica del Sacro Cuore · ITUniversity of Cagliari · ITUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Milan · ITUniversity of Modena and Reggio Emilia · ITUniversity of Rome Tor Vergata · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe development of direct-acting antivirals (DAA) for HCV has revolutionized the treatment of HCV, including its treatment in patients with HIV coinfection. The aim of this study was to compare the changes in liver function between coinfected and monoinfected patients with cirrhosis who achieved HCV eradication by DAA.

methodsPatients with pre-treatment diagnosis of HCV liver cirrhosis, consecutively enrolled in the multicenter PITER cohort, who achieved a sustained virological response 12 weeks after treatment cessation (SVR12) were analysed. Changes in Child-Pugh (C-P) class and the occurrence of a decompensating event was prospectively evaluated after the end of DAA treatment. Cox regression analysis was used to evaluate factors independently associated with changes in liver function following viral eradication.

resultsWe evaluated 1350 patients, of whom 1242 HCV monoinfected (median follow-up 24.7, range 6.8-47.5 months after viral eradication) and 108 (8%) HCV/HIV coinfected (median follow-up 27.1, range 6.0-44.6). After adjusting for age, sex, HCV-genotype, HBsAg positivity and alcohol use, HIV was independently associated with a more advanced liver disease before treatment (C-P class B/C vs A) (OR: 3.73, 95% CI:2.00-6.98). Following HCV eradication, C-P class improved in 17/20 (85%) coinfected patients (from B to A and from C to B) and in 53/82 (64.6%) monoinfected patients (from B to A) (p = 0.08). C-P class worsened in 3/56 coinfected (5.3%) (from A to B) and in 84/1024 (8.2%) monoinfected patients (p = 0.45) (from A to B or C and from B to C). Baseline factors independently associated with C-P class worsening were male sex (HR = 2.00; 95% CI = 1.18-3.36), platelet count < 100,000/μl (HR = 1.75; 95% CI 1.08-2.85) and increased INR (HR = 2.41; 95% CI 1.51-3.84). Following viral eradication, in 7 of 15 coinfected (46.6%) and in 61 of 133 (45.8%) monoinfected patients with previous history of decompensation, a new decompensating event occurred. A first decompensating event was recorded in 4 of 93 (4.3%) coinfected and in 53 of 1109 (4.8%) monoinfected patients (p = 0.83).

conclusionsImprovement of liver function was observed following HCV eradication in the majority of patients with cirrhosis; however viral eradication did not always mean cure of liver disease in both monoinfected and coinfected patients with advanced liver disease.

Indexed as

AgedAntiviral AgentsCoinfectionFemaleHepacivirusHepatitis CHIV InfectionsHumansLiver CirrhosisLiver Function TestsMaleMiddle AgedProspective StudiesSustained Virologic ResponseTreatment OutcomeAntiviral AgentsAdvanced liver diseaseDecompensated cirrhosisDirect-acting antiviralsHepatitis C virusHuman immunodeficiency virusReal-life cohort

Identifiers

PMID33947337
PMCPMC8094561
OpenAlexW3124214328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.